loading
Fate Therapeutics Inc stock is traded at $1.15, with a volume of 1.84M. It is up +3.60% in the last 24 hours and down -7.26% over the past month. Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
See More
Previous Close:
$1.11
Open:
$1.11
24h Volume:
1.84M
Relative Volume:
1.10
Market Cap:
$132.63M
Revenue:
$13.45M
Net Income/Loss:
$-178.23M
P/E Ratio:
-0.697
EPS:
-1.65
Net Cash Flow:
$-132.53M
1W Performance:
+5.50%
1M Performance:
-7.26%
6M Performance:
-19.01%
1Y Performance:
-69.50%
1-Day Range:
Value
$1.095
$1.17
1-Week Range:
Value
$1.06
$1.22
52-Week Range:
Value
$0.6611
$4.20

Fate Therapeutics Inc Stock (FATE) Company Profile

Name
Name
Fate Therapeutics Inc
Name
Phone
858.875.1803
Name
Address
12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA
Name
Employee
181
Name
Twitter
@fatethx
Name
Next Earnings Date
2025-08-08
Name
Latest SEC Filings
Name
FATE's Discussions on Twitter

Compare FATE with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
FATE
Fate Therapeutics Inc
1.15 138.40M 13.45M -178.23M -132.53M -1.65
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
395.12 99.96B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
589.48 60.83B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
454.38 59.89B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
ARGX
Argen X Se Adr
660.00 40.47B 3.06B 1.28B 447.35M 21.30
Biotechnology icon
ONC
Beone Medicines Ltd Adr
313.67 37.96B 3.81B -644.79M -669.77M -6.24

Fate Therapeutics Inc Stock (FATE) Upgrades & Downgrades

Date Action Analyst Rating Change
Nov-18-24 Upgrade BofA Securities Underperform → Neutral
Jun-17-24 Upgrade Piper Sandler Neutral → Overweight
Mar-27-23 Resumed Wells Fargo Equal Weight
Jan-24-23 Downgrade H.C. Wainwright Buy → Neutral
Jan-06-23 Downgrade BMO Capital Markets Outperform → Market Perform
Jan-06-23 Downgrade BofA Securities Buy → Underperform
Jan-06-23 Downgrade Cowen Outperform → Market Perform
Jan-06-23 Downgrade Piper Sandler Overweight → Neutral
Jan-06-23 Downgrade Stifel Buy → Hold
Jan-06-23 Downgrade Truist Buy → Hold
Jan-06-23 Downgrade Wedbush Outperform → Neutral
Jan-03-23 Downgrade Guggenheim Buy → Neutral
Dec-22-22 Downgrade Oppenheimer Outperform → Perform
Dec-15-22 Initiated Goldman Sell
Nov-04-22 Resumed Cantor Fitzgerald Overweight
Oct-10-22 Initiated Canaccord Genuity Buy
Aug-18-22 Resumed Wells Fargo Overweight
Jul-28-22 Initiated Needham Hold
Jul-11-22 Upgrade BMO Capital Markets Market Perform → Outperform
Jun-03-22 Initiated Robert W. Baird Neutral
Feb-11-22 Resumed BMO Capital Markets Market Perform
Dec-15-21 Upgrade Wedbush Neutral → Outperform
Dec-07-21 Initiated Cowen Outperform
Nov-09-21 Upgrade Citigroup Neutral → Buy
Aug-26-21 Initiated Morgan Stanley Equal-Weight
Jun-07-21 Upgrade H.C. Wainwright Neutral → Buy
May-07-21 Upgrade Wedbush Neutral → Outperform
Apr-26-21 Resumed Jefferies Buy
Feb-26-21 Initiated BofA Securities Buy
Feb-26-21 Downgrade Wedbush Outperform → Neutral
Feb-11-21 Downgrade Citigroup Buy → Neutral
Jan-27-21 Resumed H.C. Wainwright Neutral
May-13-20 Initiated H.C. Wainwright Buy
Mar-04-20 Initiated Barclays Overweight
Jan-09-20 Downgrade BMO Capital Markets Outperform → Market Perform
Dec-30-19 Reiterated Mizuho Buy
Dec-09-19 Upgrade Wells Fargo Market Perform → Outperform
Nov-12-19 Initiated SunTrust Buy
Nov-06-19 Downgrade Wells Fargo Outperform → Market Perform
Oct-01-19 Initiated Stifel Buy
Aug-09-19 Initiated BTIG Research Buy
Jul-22-19 Initiated Cantor Fitzgerald Overweight
Jul-12-19 Initiated Oppenheimer Outperform
Jun-13-19 Initiated Mizuho Buy
Jun-07-19 Initiated ROTH Capital Neutral
May-31-19 Initiated Guggenheim Buy
May-24-19 Resumed Citigroup Buy
Mar-28-19 Initiated SVB Leerink Outperform
Jan-03-19 Downgrade Stephens Overweight → Equal-Weight
Nov-05-18 Initiated Jefferies Buy
Aug-01-18 Initiated Citigroup Buy
Mar-06-18 Downgrade H.C. Wainwright Buy → Neutral
View All

Fate Therapeutics Inc Stock (FATE) Latest News

pulisher
Aug 20, 2025

Layoff Tracker: Opthea Slashes 80% of Workforce, 50% of Board - BioSpace

Aug 20, 2025
pulisher
Aug 20, 2025

Fate Therapeutics Inc. Rebound Backed by Sentiment ShiftJuly 2025 Snapshot & Precise Swing Trade Alerts - newsyoung.net

Aug 20, 2025
pulisher
Aug 20, 2025

Fate Therapeutics Announces Corporate Restructuring Plan - MSN

Aug 20, 2025
pulisher
Aug 16, 2025

Fate Therapeutics Faces Nasdaq Delisting Risk: Implications for Investors - MSN

Aug 16, 2025
pulisher
Aug 16, 2025

Live Scanner Shows Breakout on Fate Therapeutics Inc.Gold Moves & Technical Entry and Exit Alerts - metal.it

Aug 16, 2025
pulisher
Aug 16, 2025

RSI Suggests Rebound May Be Near in Fate Therapeutics Inc.Quarterly Profit Summary & Weekly Hot Stock Watchlists - kangso.co.kr

Aug 16, 2025
pulisher
Aug 15, 2025

BofA Securities Adjusts Fate Therapeutics Price Target to $2 From $2.20, Maintains Neutral Rating - MarketScreener

Aug 15, 2025
pulisher
Aug 15, 2025

Fate Therapeutics' Price Target Cut to $2.50 by Wells Fargo - AInvest

Aug 15, 2025
pulisher
Aug 15, 2025

Barclays Maintains Buy Rating on Fate Therapeutics with $2.00 Price Target - AInvest

Aug 15, 2025
pulisher
Aug 14, 2025

Is Now a Good Time to Reenter Fate Therapeutics Inc.Risk Management & Low Drawdown Momentum Trade Ideas - newsyoung.net

Aug 14, 2025
pulisher
Aug 14, 2025

Fate Therapeutics Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance

Aug 14, 2025
pulisher
Aug 14, 2025

Fate Therapeutics’ SWOT analysis: biotech stock navigates clinical progress amid financial challenges - Investing.com

Aug 14, 2025
pulisher
Aug 14, 2025

Fate Therapeutics Reports Q2 2025 Financial Results - TipRanks

Aug 14, 2025
pulisher
Aug 13, 2025

Fate Therapeutics Inc. Bounces Off Moving Average SupportCPI Data & Long-Term Growth Stock Strategies - beatles.ru

Aug 13, 2025
pulisher
Aug 13, 2025

Fate Therapeutics shares rise 4.42% after-hours after reporting better-than-expected Q2 earnings. - AInvest

Aug 13, 2025
pulisher
Aug 13, 2025

Fate Therapeutics Soars 28% on Earnings Optimism and Strategic Shifts - AInvest

Aug 13, 2025
pulisher
Aug 13, 2025

Fate Therapeutics shares surge 26.07% intraday after Q2 earnings beat expectations and cash runway extended to 2027. - AInvest

Aug 13, 2025
pulisher
Aug 13, 2025

FATE's 24.4% Surge: Clinical Breakthroughs and Strategic Restructuring Ignite Biotech Volatility - AInvest

Aug 13, 2025
pulisher
Aug 13, 2025

A Quick Look at Today's Ratings for Fate Therapeutics(FATE.US), With a Forecast Between $2 to $6 - 富途牛牛

Aug 13, 2025
pulisher
Aug 13, 2025

Fate Therapeutics: Q2 Earnings Snapshot - Greenwich Time

Aug 13, 2025
pulisher
Aug 13, 2025

Wells Fargo lowers Fate Therapeutics stock price target to $2.50 on cost cuts - Investing.com Canada

Aug 13, 2025
pulisher
Aug 13, 2025

Fate Therapeutics 2025 Q2 Earnings Narrowed Losses but Revenue Falls Sharply - AInvest

Aug 13, 2025
pulisher
Aug 13, 2025

Fate Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates - GlobeNewswire

Aug 13, 2025
pulisher
Aug 12, 2025

Bullish Divergence Spotted in Fate Therapeutics Inc. MomentumAccurate Buy Point for Momentum Stocks Detected - 선데이타임즈

Aug 12, 2025
pulisher
Aug 12, 2025

Cautious Hold Rating on Fate Therapeutics Amid Promising CAR-iT Developments and Early Stage Trials - TipRanks

Aug 12, 2025
pulisher
Aug 12, 2025

Fate Therapeutics earnings beat by $0.05, revenue topped estimates - Investing.com Canada

Aug 12, 2025
pulisher
Aug 12, 2025

Fate Therapeutics (FATE) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance

Aug 12, 2025
pulisher
Aug 12, 2025

Fate Therapeutics' Q2 2025 Earnings: A Strategic Catalyst for Long-Term Shareholder Value - AInvest

Aug 12, 2025
pulisher
Aug 12, 2025

Fate Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 12, 2025
pulisher
Aug 09, 2025

Can machine learning forecast Fate Therapeutics Inc. recoveryBuy Opportunity Forecast for Fast Traders - Newser

Aug 09, 2025
pulisher
Aug 08, 2025

What makes Fate Therapeutics Inc. stock price move sharplyHigh Conviction Stock Long-Term Summary - Newser

Aug 08, 2025
pulisher
Aug 08, 2025

Why Fate Therapeutics Inc. stock attracts strong analyst attentionFree Real Time Trade Opportunity Alerts - Newser

Aug 08, 2025
pulisher
Aug 08, 2025

Analyzing net buyer seller activity in Fate Therapeutics Inc.Free Entry and Exit Strategy Optimizer Tool - Newser

Aug 08, 2025
pulisher
Aug 08, 2025

Fate Therapeutics Inc. stock trend forecastFree Risk Controlled Picks With Real Returns - Newser

Aug 08, 2025
pulisher
Aug 08, 2025

Fate Therapeutics Inc expected to post a loss of 34 cents a shareEarnings Preview - TradingView

Aug 08, 2025
pulisher
Aug 07, 2025

Trapped Investors in Fate Therapeutics Inc. Await Breakout SignalWatchlist for Smart Swing Trading Updated - metal.it

Aug 07, 2025
pulisher
Aug 07, 2025

Fate Therapeutics shares fall 4.52% intraday due to unspecified reasons. - AInvest

Aug 07, 2025
pulisher
Aug 06, 2025

Full technical analysis of Fate Therapeutics Inc. stockSwing Trade Picks with High Potential - Newser

Aug 06, 2025
pulisher
Aug 06, 2025

Fate Therapeutics shares fall 4.17% intraday after granting non-qualified stock options to a new employee. - AInvest

Aug 06, 2025
pulisher
Aug 05, 2025

Fate Therapeutics CEO Makes a Notable Stock Sale! - TipRanks

Aug 05, 2025
pulisher
Aug 05, 2025

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Aug 05, 2025
pulisher
Aug 05, 2025

Fate Therapeutics' Strategic Talent Acquisition and Equity Incentive Program: A Catalyst for Biotech Innovation and Shareholder Value - AInvest

Aug 05, 2025
pulisher
Aug 05, 2025

Fate Therapeutics reports new employee inducement awards - MarketScreener

Aug 05, 2025
pulisher
Aug 05, 2025

Fate Therapeutics CEO Valamehr sells $15,396 in stock By Investing.com - Investing.com Nigeria

Aug 05, 2025
pulisher
Aug 05, 2025

Fate Therapeutics CEO Valamehr sells $15,396 in stock - Investing.com

Aug 05, 2025
pulisher
Aug 05, 2025

Cwm LLC Buys 37,290 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World

Aug 05, 2025
pulisher
Aug 05, 2025

Fate Therapeutics (NASDAQ:FATE) Upgraded at Wall Street Zen - Defense World

Aug 05, 2025
pulisher
Aug 04, 2025

Fate Therapeutics Inc. Nearing Breakout Level After BounceAccurate Technical Trend Reversal Picks Detected - metal.it

Aug 04, 2025
pulisher
Aug 03, 2025

What catalysts could drive Fate Therapeutics Inc. stock higher in 2025Capitalize on trading strategies that deliver - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What is the dividend policy of Fate Therapeutics Inc. stockFree Stock Market Return Analysis - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

How strong is Fate Therapeutics Inc. company’s balance sheetFree Capital Efficiency Planning - Jammu Links News

Aug 03, 2025

Fate Therapeutics Inc Stock (FATE) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Fate Therapeutics Inc Stock (FATE) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Valamehr Bahram
President and CEO
Aug 04 '25
Sale
1.06
14,466
15,396
334,898
$24.65
price up icon 0.94%
$85.04
price down icon 1.72%
$26.20
price up icon 0.73%
$110.88
price up icon 0.10%
$131.88
price down icon 0.54%
biotechnology ONC
$313.67
price down icon 0.10%
Cap:     |  Volume (24h):